Post-hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
暂无分享,去创建一个
D. de Zeeuw | R. Gansevoort | D. Kohan | A. Liew | P. Vart | Meir Schechter | N. Jongs | J. D. Smeijer | Christoph Wanner | H. Heerspink | Kam Wa Chan | S. C. Tang